Shore Capital Reaffirms "Buy" Rating for AstraZeneca (LON:AZN)

Shore Capital reissued their buy rating on shares of AstraZeneca (LON:AZN - Free Report) in a report issued on Monday, Marketbeat.com reports.

A number of other analysts have also recently commented on AZN. JPMorgan Chase & Co. restated an overweight rating on shares of AstraZeneca in a report on Thursday, April 4th. Barclays restated an overweight rating and set a £125 ($155.61) target price on shares of AstraZeneca in a report on Monday, April 8th. Jefferies Financial Group restated a hold rating and set a £110 ($136.94) target price on shares of AstraZeneca in a report on Friday, February 16th. UBS Group dropped their price target on shares of AstraZeneca from £107 ($133.20) to GBX 9,900 ($123.24) and set a sell rating on the stock in a research note on Monday, February 12th. Finally, BMO Capital Markets reiterated an outperform rating on shares of AstraZeneca in a research note on Monday, February 12th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of Hold and a consensus price target of £115.43 ($143.69).

AstraZeneca Stock Down 0.4 %

Shares of AZN stock traded down GBX 40 ($0.50) during mid-day trading on Monday, reaching £110.24 ($137.23). 1,154,394 shares of the company's stock traded hands, compared to its average volume of 2,211,943. AstraZeneca has a 12 month low of GBX 9,461 ($117.78) and a 12 month high of £123.92 ($154.26). The company has a market cap of £170.87 billion, a P/E ratio of 3,638.28, a P/E/G ratio of 0.89 and a beta of 0.19. The company has a quick ratio of 0.59, a current ratio of 0.82 and a debt-to-equity ratio of 75.70. The company's 50-day moving average price is £103.22 and its 200-day moving average price is £104.24.

AstraZeneca Increases Dividend

The firm also recently announced a dividend, which was paid on Monday, March 25th. Shareholders of record on Thursday, February 22nd were given a GBX 156 ($1.94) dividend. This is a positive change from AstraZeneca's previous dividend of $71.80. The ex-dividend date was Thursday, February 22nd. This represents a yield of 1.49%. AstraZeneca's payout ratio is 7,524.75%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.